Same word, different rulebooks: how an approved peptide medicine differs from a "wellness" peptide
Tesamorelin is a peptide with an FDA-approved label, and that label says it "is not indicated for weight loss management." BPC-157, the peptide you hear about most in gym circles, has no FDA approval and so no FDA-approved label. No FDA-reviewed document sets out what it is for, who should avoid it, or what to watch for.
Published October 25, 2026. Status is "as of" this date. Sources and retrieval dates are at the bottom. This is not medical advice. The site owner is not a medical professional. Nothing here is a recommendation to use any substance.
The short version
- An FDA-approved peptide medicine has been through an FDA review of data on its safety and effectiveness for a stated use, and it comes with an approved label. [V]
- A compounded drug is not FDA-approved, even when it contains the same active ingredient. FDA says it "does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." [V]
- A peptide with no FDA approval for human use, such as BPC-157, has neither of those things. On its compounding-safety page, FDA says it "lacks sufficient information to know whether the drug would cause harm when administered to humans." [V]
Three columns, one word
Our plain-English peptide explainer showed that "peptide" covers a prescription medicine and a gym-chat compound alike. This post puts them side by side. It compares regulatory status only. It does not say any column is right or wrong for any person.
- FDA-approved peptide medicines. Examples: semaglutide (Wegovy), tirzepatide (Zepbound) and tesamorelin (Egrifta WR). Each has a label on DailyMed, the National Library of Medicine's database of drug labels. [V]
- Compounded drugs. A pharmacy or outsourcing facility prepares these. FDA says they "are not FDA-approved," and that generics, by contrast, are approved through their own pathway. [V]
- Peptides with no FDA approval for human use. BPC-157 is the best-known example. A 2025 systematic review describes it as lacking FDA approval. [V]
The comparison
| Question | FDA-approved peptide medicine | Compounded drug | No FDA approval for human use (e.g. BPC-157) |
|---|---|---|---|
| Did FDA review data on safety and effectiveness before it was sold? | Yes. FDA approves an application after deciding the data are "adequate to show the drug's safety and effectiveness for its proposed use" [V] | No. FDA does not verify safety, effectiveness or quality before marketing [V] | No FDA approval [V] |
| Is there an FDA-approved label listing approved uses, who should not use it and warnings? | Yes, published on DailyMed [V] | No FDA-approved label, because the drug is not FDA-approved [V] | No [V] |
| What has FDA said about quality or risk? | Risks are set out in the label, for example in boxed warnings and contraindications [V] | "Poor compounding practices can result in serious drug quality problems, such as contamination or a drug that contains too much or too little active ingredient" [V] | For BPC-157, FDA cites possible immunogenicity and impurity concerns and "no, or only limited, safety-related information" [V] |
| What human evidence is behind it? | Clinical trials submitted to FDA (FDA's application must include everything "from preclinical data to Phase 3 trial data") [V] | Depends on the ingredient; the compounded product itself is not reviewed [V] | For BPC-157, one 2025 review found 35 preclinical studies and 1 clinical study [V] |
What an approved label actually tells you
A label is not marketing copy. It is the document FDA approved alongside the drug, and it is narrower than most people expect.
- Zepbound (tirzepatide) is indicated, with diet and exercise, for weight reduction in certain adults and to treat moderate to severe obstructive sleep apnea in adults with obesity. Its label says taking it with other tirzepatide products or any GLP-1 receptor agonist "is not recommended." [V]
- Egrifta WR (tesamorelin), described on its label as "a human growth hormone-releasing factor (GRF) analog," is indicated "for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy." The label adds that it "is not indicated for weight loss management as it has a weight neutral effect." [V]
- Wegovy (semaglutide) lists uses including reducing the risk of major cardiovascular events in certain adults, long-term weight reduction, and a liver condition called MASH. [V]
- The Wegovy and Zepbound labels both open with a boxed warning about thyroid C-cell tumors seen in rodents. They say it is unknown whether the drug causes these tumors in humans. [V]
The point for a reader is that "approved" always comes with "for what, and for whom." An approval for one use in one group is not an approval for every use you hear about online.
Where the other two columns come from
FDA says compounding can serve "an important patient need," for example a patient allergic to a dye or a child who cannot swallow a tablet. It also says compounded drugs "should only be used in patients whose medical needs cannot be met by an FDA-approved drug." [V] The rules for which bulk ingredients compounders may use are explained in our Category 1 and 2 explainer. How telehealth firms market compounded drugs is covered in our FTC and FDA telehealth post.
For peptides with no approval, the record is thinner. FDA's compounding-safety page lists BPC-157 among substances whose nominations were withdrawn, and it keeps FDA's description of potential risks. [V] Our evidence ladder walks through what the published BPC-157 research does and does not show. For athletes, sport rules are a separate question, covered in our WADA explainer.
What the table does not say
It does not say an approved medicine is right for you. A label lists who should not use a drug, and only a clinician who knows your history can apply it. It also does not say a substance without approval has been shown to be harmful. FDA's own wording for BPC-157 is that it lacks the information to know. "Not reviewed" and "proven unsafe" are different findings.
Why you should care
When a post, ad or friend calls something "a peptide," the word hides which column it sits in. That column decides whether anyone checked the product's quality before it was sold, and whether an official label exists to tell you who should avoid it. Getting the column right comes before any question about results.
What to do with this
These are questions to ask, not advice:
- Which column is this? An FDA-approved medicine, a compounded drug, or a substance with no FDA approval for human use?
- If it is approved, for what and for whom? The indication on DailyMed is the approved use. Anything else is not covered by that approval.
- If it is compounded, who made it, and why is an approved drug not being used? FDA frames compounding around needs an approved drug cannot meet.
- If it has no approval, what evidence is being cited? People, animals or cells?
- Have I asked a clinician or pharmacist who knows my health history? They can tell you what applies to you. This site cannot.
What to watch next
- FDA's next compounding advisory committee meeting, expected before the end of February 2027, will consider five substances including GHK-Cu. See our GHK-Cu explainer and the regulation timeline.
- This week's developments are in our weekly roundup.
Sources (all retrieved October 25, 2026)
- FDA, "Compounding and the FDA: Questions and Answers," content current as of 09/16/2025 [V] — https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- FDA, "Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)," content current as of 09/11/2024, for the definition of a drug and the NDA approval standard [V] — https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soap
- FDA, "Step 4: FDA Drug Review," The Drug Development Process, content current as of 01/04/2018 [V] — https://www.fda.gov/patients/drug-development-process/step-4-fda-drug-review
- DailyMed, ZEPBOUND (tirzepatide) label, set id 487cd7e7-434c-4925-99fa-aa80b1cc776b, version 40, published September 2, 2026 [V] — https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/487cd7e7-434c-4925-99fa-aa80b1cc776b.xml
- DailyMed, EGRIFTA WR (tesamorelin) label, set id 839334d3-8c1d-4c26-9036-2ab524a6ea75, version 2, published August 3, 2026 [V] — https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/839334d3-8c1d-4c26-9036-2ab524a6ea75.xml
- DailyMed, WEGOVY (semaglutide) label, set id ee06186f-2aa3-4990-a760-757579d8f77b, version 19, published June 30, 2026 [V] — https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/ee06186f-2aa3-4990-a760-757579d8f77b.xml
- FDA, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (Category 2 page), content current as of 04/22/2026 [V] — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Vasireddi N, et al., "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review," HSS Journal, 2025 [V, abstract read on PubMed] — https://pubmed.ncbi.nlm.nih.gov/40756949/
- FDA, Pharmacy Compounding Advisory Committee meeting page (early announcement), content current as of 04/15/2026 [V] — https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee
Reading this for health reasons? This site reports on regulation; it is not medical advice. See our disclaimer, how we source and corrections policy.